Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

Melanoma | Oncology Today with Dr Neil Love: Novel Immunotherapeutic Strategies in Melanoma Dec 13, 2022

Show notes

Featuring an interview with Dr Omid Hamid, including the following topics:

First-line treatment of metastatic melanoma (0:00)
Triplet therapy for patients with BRAF-mutated metastatic melanoma (7:27)
Case: A man in his mid 60s with previously untreated BRAF wild-type metastatic melanoma (15:44)
Novel therapeutic strategies for patients with newly diagnosed melanoma (21:02)
Immunotherapy strategies for second-line treatment of metastatic melanoma (29:25)
Case: A man in his mid 40s with BRAF-mutated melanoma who experiences disease progression after treatment with ipilimumab and nivolumab (37:16)

CME information and select publications

Thyroid Cancer | Oncology Today with Dr Neil Love: Thyroid Cancer (Companion Faculty Lecture) Dec 08, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Eric Sherman, including the following topics:

Incidence and mortality of thyroid cancer and the thyroid cancer treatment pyramid (0:00)
Available and emerging data with targeted therapies for thyroid cancer (9:01)
Optimal genomic screening and selection of treatment for medullary thyroid cancer (26:58)

CME information and select publications

Thyroid Cancer | Oncology Today with Dr Neil Love: Thyroid Cancer Dec 08, 2022

Show notes

Featuring an interview with Dr Eric Sherman, including the following topics:

Changes in the incidence, mortality, and management of thyroid cancer in the past 20 years (0:00)
Clinical presentation and histologic characteristics of thyroid cancer; genomic alterations associated with each histology (5:55)
Initial management of thyroid cancer; current role of surgery and radioactive iodine in treatment algorithms (14:56)
Current and future role of tumor biomarkers in treatment selection; emerging role of liquid biopsies in anaplastic thyroid cancer (20:23)
Incidence and optimal treatment of brain metastases in patients with thyroid cancer; biologic rationale for tyrosine kinase inhibitors (TKIs) targeting VEGF and BRAF in thyroid cancer (24:20)
Safety and tolerability of sorafenib and lenvatinib; management of BRAF-mutated disease (34:49)
Management of tumors in patients with RET alterations or NTRK fusions; therapies for medullary tumors (39:28)
Case: A woman in her early 60s with metastatic papillary thyroid cancer; ongoing research combining TKIs and immunotherapy for anaplastic thyroid cancer (50:35)
Case: A man in his early 40s presenting with severe diarrhea and metastatic medullary thyroid cancer (1:00:54)

CME information and select publications

Meet The Professor: Optimizing the Use of Hormonal Therapy in the Management of Prostate Cancer — Part 2 Dec 07, 2022

Show notes

Featuring perspectives from Prof Karim Fizazi and Prof Stéphane Oudard, including the following topics:

Introduction: Journal Club — Karim Fizazi, MD, PhD and Stéphane Oudard, MD, PhD (0:00)
Case: A man in his late 50s with Gleason 7 prostate cancer after prostatectomy/radiation therapy/androgen deprivation therapy (ADT) experiences biochemical recurrence 2 years later (PSA 0.5; doubling time 9 months) — Philip L Brooks, MD (10:58)
Case: A man in his early 70s with a pacemaker presents with de novo metastatic hormone-sensitive prostate cancer (mHSPC) after cerebrovascular accident — Nasfat Shehadeh, MD (28:50)
Case: A man in his late 40s with multiple medical comorbidities presents with de novo mHSPC (PSA 19.4) and responds to ADT/docetaxel — Gurveen Kaur, MD (47:00)
Case: A man in his mid 60s with de novo mHSPC receives leuprolide, and PSA levels decrease from 865 ng/mL to 1.34 ng/mL — Joanna Metzner-Sadurski, MD (50:38)
Case: A man in his late 50s with mHSPC receives leuprolide, experiences disease progression 1.5 years later and responds to abiraterone/prednisone but on liquid biopsy is found to have an AR T878 mutation — Niyati A Nathwani, MD (54:30)
Case: A man in his mid 60s presents with de novo metastatic prostate cancer and experiences disease progression on ADT + docetaxel, now with progressive disease on abiraterone/prednisone; germline CHEK2 mutation — Syed F Zafar, MD (56:51)

CME information and select publications

Amyloid Light Chain (AL) Amyloidosis | Oncology Today with Dr Neil Love: Amyloid Light Chain (AL) Amyloidosis (Companion Faculty Lecture) Dec 06, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Jeffrey Zonder, including the following topics:

Overview of amyloid light chain (AL) amyloidosis (0:00)
Case: An African American man in his late 70s with transthyretin amyloidosis (8:39)
Staging and prognosis of AL amyloidosis (14:11)
Evolution of the amyloidosis treatment paradigm (26:39)
Case: A woman in her late 70s with relapsed lambda light chain amyloidosis (44:33)
Emerging data with novel therapies for AL amyloidosis (47:38)
Case: A man in his early 60s with relapsed lambda light chain amyloidosis (52:18)

CME information and select publications

Amyloid Light Chain (AL) Amyloidosis | Oncology Today with Dr Neil Love: Amyloid Light Chain (AL) Amyloidosis Dec 06, 2022

Show notes

Featuring an interview with Dr Jeffrey Zonder, including the following topics:

Biology and symptomology of primary amyloidosis (0:00)
Staging and prognosis for patients with amyloid light chain (AL) amyloidosis (10:21)
Supportive care for patients with advanced disease (16:25)
Current amyloidosis treatment paradigm (21:49)
Monoclonal antibody therapy for patients with AL amyloidosis (31:38)

CME information and select publications

Acute Myeloid Leukemia | Oncology Today with Dr Neil Love — Novel Agents and Strategies in AML Dec 05, 2022

Show notes

Featuring perspectives from Dr Daniel Pollyea, including the following topics:

Introduction (0:00)
Acute Myeloid Leukemia (AML), 2014 to 2022 (3:35)
Defining AML versus Myelodysplastic Syndromes (6:06)
Case: A man in his early 80s presenting with cytopenias and AML (8:56)
Oral Decitabine/Cedazuridine (18:15)
Management of Cytopenias with HMA (Hypomethylating Agent)/Venetoclax: Drug-Drug Interactions (26:43)
HMA/Venetoclax for Younger Patients (39:56)
Translational Biology of AML: New Agents and Treatment Strategies (44:08)
Case: A man in his mid 70s with p53-mutated AML and complex karyotype (47:48)
Anti-CD47 Antibody Magrolimab (51:08)
Case: A woman in her early 60s with MLL-rearranged AML after receiving 7 + 3, FLAG-IDA and azacitidine/venetoclax (54:22)

CME information and select publications

Multiple Myeloma | Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 2 Dec 02, 2022

Show notes

Featuring perspectives from Dr Paul Richardson, including the following topics:

Introduction (0:00)
Case: A man in his early 60s with newly diagnosed Stage II standard-risk multiple myeloma — Ranju Gupta, MD (29:31)
Case: A woman in her early 70s with Stage IIIA multiple myeloma who receives lenalidomide/bortezomib/dexamethasone → autologous stem cell transplant (ASCT) and discontinues maintenance lenalidomide after 3 years — Erik Rupard, MD (34:16)
Case: A woman in her early 70s with relapsed myeloma after tandem ASCT who receives cyclophosphamide/bortezomib/dexamethasone, achieves minimum residual disease negativity and is now on maintenance ixazomib — Zanetta S Lamar, MD (39:01)
Case: A woman in her early 70s with triple-class refractory t(11;14) multiple myeloma — Hans Lee, MD (43:47)
Case: A man in his mid 60s with high-risk relapsed multiple myeloma after carfilzomib/lenalidomide/dexamethasone (KRd) induction, ASCT, maintenance KRd and 2 additional lines of therapy — Muzaffar H Qazilbash, MD (46:05)
Faculty Survey (52:29)
Journal Club with Dr Richardson (60:57)

CME information and select publications

Myelofibrosis | Oncology Today with Dr Neil Love: Novel Agents and Strategies in Myelofibrosis (Companion Faculty Lecture) Dec 01, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Ruben Mesa, including the following topics:

Efficacy and safety of FDA-approved JAK inhibitors for the management of myelofibrosis (MF) (0:00)
Emerging JAK inhibitors under Phase III evaluation for MF (6:59)
Current guidelines and strategies for managing MF (13:53)
Emerging data with novel agents and strategies for MF (17:31)
Splenic response and symptomology in patients with MF (25:36)

CME information and select publications

Myelofibrosis | Oncology Today with Dr Neil Love: Novel Agents and Strategies in Myelofibrosis Dec 01, 2022

Show notes

Featuring an interview with Dr Ruben Mesa, including the following topics:

Managing myelofibrosis (MF) before the availability of ruxolitinib (0:00)
Pathobiology and mutational profile of MF (7:33)
Matching treatments to individual patients with MF (13:25)
Case: A man in his early 70s with MF and worsening anemia (17:13)
Case: A man in his late 60s initially diagnosed with polycythemia vera now with MF requiring therapy (23:15)
Case: A woman in her mid 60s with MF that has a suboptimal response to first-line JAK inhibitor therapy (30:25)
Efficacy and safety of novel agents and strategies for MF (35:40)

CME information and select publications